Kay Hagan
The Public Record
Kay Hagan is a former United States Senator from North Carolina, serving from 2009 to 2015. A member of the Democratic Party, she was the first woman to represent North Carolina in the Senate. Hagan focused on issues such as healthcare, education, and economic recovery during her time in office. She was known for her moderate stance and worked across party lines on various initiatives. Hagan lost her re-election bid in 2014 to Republican Thom Tillis, marking the end of her Senate career.
Raising taxes in the middle of a three-year recession and not having that certainty and stability is a problem.
I was happy and honored to sign on to the bill of Senators Landrieu and Snowe.
I introduced the Democratizing Access to Capital Act, which allows for crowdfunding.
I, too, was very--have always been concerned about the lack of financial literacy being taught to our students.
The Center for Responsible Lending has indicated that these loans are marketed as short-term but often keep customers in debt for an average of 175 days a year.
I ask unanimous consent that all time in the quorum call be divided equally. The PRESIDING OFFICER. Without objection, it is so ordered.
I wish to thank the chairman and the ranking member for allowing this colloquy to take place. I also wish to state that I believe the Senator from Oklahoma laid out a little bit of the groundwork of what we are discussing now. I rise to…
What we're doing works, but we don't really necessarily have the tools and the authority.
I'm concerned, obviously, about this issue, and I've got a particularly heart-wrenching story I wanted to share.
I introduced the Preserving Access to Life-Saving Medications Act with Senator Casey of Pennsylvania.
It's very complicated to look at what these causes are and to figure out the long-term solutions.
I was proud to support his nomination to become the first Director of the Consumer Financial Protection Bureau.
Dodd-Frank represents a major step forward on this issue by granting important new authorities to our prudential regulators.
We need a strong Director to help improve the oversight over these predatory lenders who continue to prey on American families across our country.
today I am proud to introduce the March of Dimes Commemorative Coin Act. For almost 75 years, the March of Dimes has fought to combat and prevent diseases that strike our youngest children, while also supporting mothers-to-be and families…
today I wish to recognize the dedication and selfless service of the Montford Point Marines. The Montford Point Marines were the first African-American men to serve in the U.S. Marine Corps after President Franklin Roosevelt issued…
If I reference the IOM report again here, in the United States, use of clinical data in the regulatory review process is defined by the enabling legislation, regulations and FDA's implementation of the legislation and regulations.
I really remain concerned about their force protection, the individuals that are remaining in Iraq.
Iraqi counterterrorism forces in partnership with the U.S. special operations personnel have significantly degraded al Qaeda in Iraq's ability to conduct these spectacular attacks.
One complaint that I continue to hear from constituent companies is that the FDA's medical device review process is unpredictable and inconsistent.





